Overview

• Regeneron Pharmaceuticals has agreed to purchase 23andMe’s assets for $256 million following a court-supervised bankruptcy auction.
• The acquisition includes 23andMe’s genetic data from 15 million customers, along with its Personal Genome Service and research services.
• Regeneron has pledged to comply with 23andMe’s existing privacy policies and laws, with oversight from a court-appointed consumer privacy ombudsman.
• Lemonaid Health, 23andMe’s telehealth subsidiary, is excluded from the deal and will be wound down by the company.
• The transaction requires U.S. Bankruptcy Court approval on June 17, with a closing expected in the third quarter of 2025.